594 results on '"Sibila, Oriol"'
Search Results
2. Bronchoalveolar cytokine profile differentiates Pulmonary Langerhans cell histiocytosis patients from other smoking-related interstitial lung diseases
3. The U-Shaped Relationship Between Eosinophil Count and Bronchiectasis Severity: The Effect of Inhaled Corticosteroids
4. Validity of prognostic models of critical COVID-19 is variable. A systematic review with external validation
5. Pathophysiology of Chronic Bronchial Infection in Bronchiectasis
6. Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia
7. Airway IL-1β is related to disease severity and mucociliary function in bronchiectasis
8. Endotypes of Exacerbation in Bronchiectasis: An Observational Cohort Study
9. Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
10. The 7 Cardinal Sins of COPD in Spain
11. [Translated article] Biological Biomarkers in Respiratory Diseases
12. Biomarcadores biológicos en las enfermedades respiratorias
13. Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge
14. Breath analysis using electronic nose and gas chromatography-mass spectrometry: A pilot study on bronchial infections in bronchiectasis
15. C-reactive protein isoforms as prognostic markers of COVID-19 severity.
16. The Association between Bronchiectasis and Chronic Obstructive Pulmonary Disease: Data from the European Bronchiectasis Registry (EMBARC).
17. COVID-19 and lung involvement
18. Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study
19. C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON)
20. RIBRON: The Spanish online bronchiectasis registry. Characterization of the first 1912 patients
21. RIBRON: el registro español informatizado de bronquiectasias. Caracterización de los primeros 1.912 pacientes
22. Documento de consenso de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) para el seguimiento clínico post-COVID-19
23. Documento de consenso sobre el diagnóstico y tratamiento de la infección bronquial crónica en la enfermedad pulmonar obstructiva crónica
24. Inflamación local y sistémica en bronquiectasias. Endotipos y biomarcadores
25. COPD Assessment Test in Bronchiectasis: Minimum Clinically Important Difference and Psychometric Validation: A Prospective Study
26. Persistent Respiratory Failure and Re-Admission in Patients with Chronic Obstructive Pulmonary Disease Following Hospitalization for COVID-19
27. Role of respiratory intermediate care units during the SARS-CoV-2 pandemic
28. Low birth weight as a potential risk factor for severe COVID-19 in adults
29. Pathophysiology, Immunology, and Histopathology of Bronchiectasis
30. An international perspective on hospitalized patients with viral community-acquired pneumonia
31. Risk of SARS-CoV-2 Infection and Disease Severity Among People With Bronchiectasis: Analysis of Three Population Registries.
32. Inflammatory Molecular Endotypes in Bronchiectasis: A European Multicenter Cohort Study
33. Telomere length in patients with bronchiectasis
34. The bronchiectasis exacerbation definition in a real-world setting: data from the EMBARC registry
35. Risk of SARS-CoV-2 infection and disease severity among people with bronchiectasis: analysis of three population registries
36. The airway microbiome in Bronchiectasis-COPD overlap: data from the EMBARC-BRIDGE study
37. Is the association between the severity of airflow limitation and DNA Methylation similar in blood and lung tissue in patients with COPD?
38. Alpha-1 antitrypsin deficiency genotypes in a large international cohort study of bronchiectasis (EMBARC BRIDGE)
39. Convergent validity of the Bronchiectasis Impact Measure: data from the EMBARC-BRIDGE study
40. Abnormal immune response in patients with persistent lung sequelae after COVID-19
41. Inflammatory Endotypes, Microbiome and Exacerbation Risk in Bronchiectasis: A European Multicentre Study
42. Risk of SARS-CoV-2 Infection and Disease Severity Among People With Bronchiectasis
43. Bronchiectasis: Changes in the Characterization of Patients During 20 Years of Follow-up. Data from the Spanish Bronchiectasis Registries
44. Identification of Pseudomonas aeruginosa and airway bacterial colonization by an electronic nose in bronchiectasis
45. Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review
46. Residual pulmonary infiltrates, symptoms and diffusion impairment at one‐year after severe COVID‐19 infection have different associated factors
47. Persistence of a SARS-CoV-2 T-cell response in patients with long COVID and lung sequelae after COVID-19
48. Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis
49. Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity
50. Inflammatory Molecular Endotypes in Bronchiectasis: A European Multicenter Cohort Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.